RU2010113998A - Применение пептида rfmwmr в качестве терапевтического средства - Google Patents
Применение пептида rfmwmr в качестве терапевтического средства Download PDFInfo
- Publication number
- RU2010113998A RU2010113998A RU2010113998/15A RU2010113998A RU2010113998A RU 2010113998 A RU2010113998 A RU 2010113998A RU 2010113998/15 A RU2010113998/15 A RU 2010113998/15A RU 2010113998 A RU2010113998 A RU 2010113998A RU 2010113998 A RU2010113998 A RU 2010113998A
- Authority
- RU
- Russia
- Prior art keywords
- diseases
- pharmaceutical composition
- peptide
- arg
- met
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/085—Angiotensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
Abstract
1. Применение пептида Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 и его деацетилированной формы для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 2. Применение пептида по п.1, где инфекционное заболевание выбрано из инфекции Mycobacterium tuberculosis и инфекционных заболеваний, вызванных инфекцией Mycobacterium tuberculosis, выбранных из инфекционных заболеваний легкого, центральной нервной системы, лимфатической системы, системы кровообращения, мочеполовой системы, костей, суставов и кожи. ! 3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава. ! 5. Фармацевтическая композиция, содержащая пептид Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 и его деацетилированную форму совместно с по меньшей мере одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем. ! 6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора. ! 7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции. ! 8. Фармацевтическая композиция по п.5 или 6 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясель�
Claims (9)
1. Применение пептида Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 и его деацетилированной формы для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
2. Применение пептида по п.1, где инфекционное заболевание выбрано из инфекции Mycobacterium tuberculosis и инфекционных заболеваний, вызванных инфекцией Mycobacterium tuberculosis, выбранных из инфекционных заболеваний легкого, центральной нервной системы, лимфатической системы, системы кровообращения, мочеполовой системы, костей, суставов и кожи.
3. Применение пептида по п.1 или 2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
4. Применение пептида по п.1 или 2 для получения лиофилизированного состава или буферного жидкого состава.
5. Фармацевтическая композиция, содержащая пептид Ac-Arg-Phe-Met-Trp-Met-Arg-NH2 и его деацетилированную форму совместно с по меньшей мере одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
6. Фармацевтическая композиция по п.5 в форме лиофилизата или жидкого буферного раствора.
7. Фармацевтическая композиция по п.5 или 6, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
8. Фармацевтическая композиция по п.5 или 6 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
9. Фармацевтическая композиция по п.5 или 6, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезней обмена веществ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07017762.1 | 2007-09-11 | ||
| EP07017762 | 2007-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010113998A true RU2010113998A (ru) | 2011-10-20 |
Family
ID=40336638
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113992/15A RU2010113992A (ru) | 2007-09-11 | 2008-09-09 | Применение урокортина и кортиколиберина в качестве терапевтических средств |
| RU2010113998/15A RU2010113998A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида rfmwmr в качестве терапевтического средства |
| RU2010114028/15A RU2010114028A (ru) | 2007-09-11 | 2008-09-09 | Применение ангиотензина ii в качестве терапевтического средства, например, при инфекции s. pneumoniae |
| RU2010114006/15A RU2010114006A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010113992/15A RU2010113992A (ru) | 2007-09-11 | 2008-09-09 | Применение урокортина и кортиколиберина в качестве терапевтических средств |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010114028/15A RU2010114028A (ru) | 2007-09-11 | 2008-09-09 | Применение ангиотензина ii в качестве терапевтического средства, например, при инфекции s. pneumoniae |
| RU2010114006/15A RU2010114006A (ru) | 2007-09-11 | 2008-09-09 | Применение пептида в качестве терапевтического средства |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8338380B2 (ru) |
| EP (4) | EP2190465A2 (ru) |
| JP (4) | JP2010538980A (ru) |
| KR (4) | KR20100058552A (ru) |
| AU (4) | AU2008303896A1 (ru) |
| CA (4) | CA2699109A1 (ru) |
| RU (4) | RU2010113992A (ru) |
| WO (11) | WO2009040051A2 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9192522B2 (en) | 2003-05-02 | 2015-11-24 | Eveready Battery Company, Inc. | Tampon assembly having shaped pledget |
| US8796416B1 (en) * | 2010-10-25 | 2014-08-05 | Questcor Pharmaceuticals, Inc | ACTH prophylactic treatment of renal disorders |
| DE102012004589A1 (de) * | 2012-03-09 | 2013-09-12 | Forschungszentrum Jülich GmbH | Agonisten des Angiotensin II AT2-Rezeptors zur Behandlung neurodegenerativer Erkrankungen |
| WO2014021942A1 (en) * | 2012-08-01 | 2014-02-06 | University Of Southern California | Methods for limiting development of neurodegeneration |
| US20140294923A1 (en) * | 2013-02-20 | 2014-10-02 | Questcor Pharmaceuticals, Inc. | Acth for treatment of migraine headache |
| WO2014153221A2 (en) * | 2013-03-14 | 2014-09-25 | Questcor Pharmaceuticals, Inc. | Acth for treatment of acute respiratory distress syndrome |
| EP2968441A1 (en) * | 2013-03-15 | 2016-01-20 | University of Southern California | Methods for treating multiple sclerosis |
| EP2967049B1 (en) | 2013-03-15 | 2020-09-02 | University Of Southern California | Methods, compounds, and compositions for the treatment of angiotensin-related diseases |
| CN104277105B (zh) * | 2013-07-12 | 2017-12-12 | 国家纳米科学中心 | 抑制β淀粉样蛋白聚集和毒性的多肽抑制剂及其应用 |
| WO2016153558A1 (en) * | 2015-03-20 | 2016-09-29 | Atkinson Arthur J | Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps |
| CN110072391A (zh) * | 2016-10-06 | 2019-07-30 | 玛托克控股有限公司 | 抗微生物组合物 |
| WO2023044487A1 (en) * | 2021-09-17 | 2023-03-23 | Peptilogics, Inc. | Treatment of lung disease or injury using engineered antimicrobial peptides |
| CN115521956B (zh) * | 2022-10-21 | 2024-04-19 | 江苏诚信药业有限公司 | 一种生物酶催化合成l-肌肽的方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US447471A (en) | 1891-03-03 | John f | ||
| US4100271A (en) | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
| US4235988A (en) | 1976-12-13 | 1980-11-25 | Imperial Chemical Industries Limited | Delivery means for biologically active agents |
| US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4474753A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
| US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
| US4801612A (en) * | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
| US5015629A (en) * | 1989-06-26 | 1991-05-14 | University Of Southern California | Tissue repair |
| US5256396A (en) | 1990-01-24 | 1993-10-26 | Colgate-Palmolive Company | Topical composition |
| CA2090860C (en) * | 1990-11-21 | 2003-09-16 | Richard A. Houghten | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| DE4110422A1 (de) * | 1991-03-29 | 1992-10-01 | Bissendorf Peptide Gmbh | Arzneimittel enthaltend humanes corticotropin-releasing hormon (crh) und/oder dessen derivate und/oder glucocorticoide natuerlicher und/oder synthetischer provenienz |
| ES2110986T3 (es) | 1991-08-12 | 1998-03-01 | Nestle Sa | Composicion alimenticia. |
| AU706333B2 (en) * | 1993-09-24 | 1999-06-17 | University Of Southern California | Use of angiotensin III and analogs thereof in tissue repair |
| WO1997000063A2 (en) * | 1995-06-13 | 1997-01-03 | The Salk Institute For Biological Studies | Urocortin peptides |
| ATE237362T1 (de) | 1996-02-19 | 2003-05-15 | Amersham Health As | Thermostabilisiertes kontrastmittel |
| US5869450A (en) * | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
| TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
| EP0832565B1 (fr) | 1996-09-24 | 2000-06-07 | Societe Des Produits Nestle S.A. | Substitut de lait et procédé de fabrication |
| US6239109B1 (en) * | 1998-02-09 | 2001-05-29 | University Of Southern California | Method of promoting erythropoiesis |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| AU771034B2 (en) | 1998-11-24 | 2004-03-11 | Societe Des Produits Nestle S.A. | Method for preparing a protein composition and an infant formula containing same |
| US7244710B2 (en) * | 2002-05-21 | 2007-07-17 | Zengen, Inc. | Treatment of ophthalmic infections using antimicrobial peptides |
| US6319900B1 (en) * | 1999-09-21 | 2001-11-20 | The Regents Of The University Of California | Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| WO2001022991A1 (en) * | 1999-09-29 | 2001-04-05 | Berg Anna Lena | Acth treatment of steroid- and statin-treated patients |
| EP1272209A1 (en) * | 2000-03-31 | 2003-01-08 | Aventis Pharmaceuticals Products Inc. | Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases |
| DE60128572T2 (de) | 2001-11-23 | 2008-02-07 | Société des Produits Nestlé S.A. | Verfahren zur Herstellung von Milchpulver und konzentrierten Milchprodukten |
| WO2004043396A2 (en) * | 2002-11-09 | 2004-05-27 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
| US20070053954A1 (en) * | 2003-10-24 | 2007-03-08 | Rowe Stephen C | Macromer-melt formulations |
| ES2318294T3 (es) * | 2004-06-01 | 2009-05-01 | Council Of Scientific And Industrial Research | Antagonistas peptidicos para inhibir la proteina de choque termico (hsp 16.3) de mycobacterium tuberculosis. |
| KR101235723B1 (ko) * | 2004-07-08 | 2013-02-21 | 아임스코 리미티드 | 약제 |
| RU2407751C2 (ru) * | 2004-10-27 | 2010-12-27 | Юниверсити Оф Денвер | Аналоги адренокортикотропного гормона и относящиеся к ним методы |
| EP1773870B1 (en) * | 2005-05-03 | 2009-12-16 | Novetide Ltd. | Methods for the production of peptide having a c-terminal amide |
| US20080207490A1 (en) * | 2005-07-07 | 2008-08-28 | Postech Foundation | Glucose Uptake Modulator and Method for Treating Diabetes or Diabetic Complications |
| WO2007104173A2 (de) | 2006-03-10 | 2007-09-20 | Laboswiss Ag | Verfahren zum solubilisieren, dispergieren und stabilisieren von stoffen, nach dem verfahren hergestellte erzeugnisse sowie die verwendung derselben |
| KR20100056515A (ko) * | 2007-09-11 | 2010-05-27 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드의 용도 |
| WO2009033792A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent |
-
2008
- 2008-09-09 WO PCT/EP2008/007811 patent/WO2009040051A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007793 patent/WO2009033745A2/en active Application Filing
- 2008-09-09 AU AU2008303896A patent/AU2008303896A1/en not_active Abandoned
- 2008-09-09 US US12/677,290 patent/US8338380B2/en not_active Expired - Fee Related
- 2008-09-09 CA CA2699109A patent/CA2699109A1/en not_active Abandoned
- 2008-09-09 RU RU2010113992/15A patent/RU2010113992A/ru not_active Application Discontinuation
- 2008-09-09 US US12/676,932 patent/US20100197604A1/en not_active Abandoned
- 2008-09-09 AU AU2008303919A patent/AU2008303919A1/en not_active Abandoned
- 2008-09-09 JP JP2010523351A patent/JP2010538980A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007437 patent/WO2009039957A2/en active Application Filing
- 2008-09-09 JP JP2010523394A patent/JP5385283B2/ja not_active Expired - Fee Related
- 2008-09-09 RU RU2010113998/15A patent/RU2010113998A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007510 patent/WO2009039968A2/en active Application Filing
- 2008-09-09 EP EP08802270A patent/EP2190465A2/en not_active Withdrawn
- 2008-09-09 JP JP2010523408A patent/JP2010539035A/ja active Pending
- 2008-09-09 AU AU2008306272A patent/AU2008306272A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007647 patent/WO2009043467A1/en active Application Filing
- 2008-09-09 CA CA2698751A patent/CA2698751A1/en not_active Abandoned
- 2008-09-09 JP JP2010523387A patent/JP5385281B2/ja not_active Expired - Fee Related
- 2008-09-09 CA CA2698673A patent/CA2698673A1/en not_active Abandoned
- 2008-09-09 US US12/677,303 patent/US20100210533A1/en not_active Abandoned
- 2008-09-09 EP EP08785857A patent/EP2197465A2/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007971 patent/WO2009033787A2/en active Application Filing
- 2008-09-09 US US12/677,519 patent/US20100204131A1/en not_active Abandoned
- 2008-09-09 EP EP08802152A patent/EP2187913B1/en not_active Not-in-force
- 2008-09-09 RU RU2010114028/15A patent/RU2010114028A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007944 patent/WO2009040073A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007636 patent/WO2009043456A2/en active Application Filing
- 2008-09-09 KR KR1020107005610A patent/KR20100058552A/ko not_active Application Discontinuation
- 2008-09-09 EP EP08802191A patent/EP2187940B1/en not_active Not-in-force
- 2008-09-09 WO PCT/EP2008/007601 patent/WO2009040005A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007741 patent/WO2009040032A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007943 patent/WO2009040072A2/en active Application Filing
- 2008-09-09 KR KR1020107005619A patent/KR20100056514A/ko not_active Application Discontinuation
- 2008-09-09 CA CA2699069A patent/CA2699069A1/en not_active Abandoned
- 2008-09-09 AU AU2008303869A patent/AU2008303869A1/en not_active Abandoned
- 2008-09-09 RU RU2010114006/15A patent/RU2010114006A/ru not_active Application Discontinuation
- 2008-09-09 KR KR1020107005639A patent/KR20100056518A/ko not_active Application Discontinuation
- 2008-09-09 KR KR1020107005591A patent/KR20100057047A/ko not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010113974A (ru) | Применение противовоспалительного пептида-1 в качестве терапевтического средства | |
| RU2010114024A (ru) | Применение гонадорелина в качестве терапевтического средства | |
| RU2010113998A (ru) | Применение пептида rfmwmr в качестве терапевтического средства | |
| RU2010113986A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114027A (ru) | Большой гастрин i в качестве терапевтического средства | |
| RU2010114031A (ru) | Проадреномедуллин индивидуально или в сочетании с большим гастрином i в качестве терапевтического средства | |
| RU2010114042A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114014A (ru) | Применение глюкагона (1-29) отдельно или в сочетании с нейропептидом w30 в качестве терапевтического средства | |
| RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114044A (ru) | Применение белка полосы 3 (824-829) и/или фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
| RU2010113983A (ru) | Применение туфтсина в качестве терапевтического средства | |
| RU2010114054A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114032A (ru) | Применение салусина бета индивидуально или в комбинации с октреотидом в качестве терапевтического средства | |
| RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114039A (ru) | Применение октреотида в качестве терапевтического средства | |
| RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
| RU2010114035A (ru) | Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства | |
| RU2010114005A (ru) | Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства | |
| RU2010114060A (ru) | Применение пептида в качестве терапевтического средства | |
| RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20110912 |